ChemoCentryx Files for IPO

ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has filed for a $57.5 million IPO. It plans to trade on the Nasdaq under ticker symbol CCXI, with Credit Suisse serving as lead underwriter. The company has raised around $105 million in VC funding, from firms like Glaxo Group (13.1% pre-IPO stake), OrbiMed Advisors (12.8%), HBM BioVentures (9.8%), Alta Partners (7.6%) HealthCap (7.4%) and GIMV.